Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 3, 2015
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - August 3, 2015

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/3/15 - /OFF HOLD OFF HOLD OFF HOLD FN Media Group LLC/
/OFF HOLD OFF HOLD OFF HOLD FN Media Group LLC, PIV757417 The following release: "Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products& Treatments for Critical-Care Patients With Severe Wound Conditions" is now OFF HOLD. Biotech companies with recent developments, partnerships and advancements in f
8/3/15 - 3-V Biosciences to Present at the 2015 Wedbush PacGrow Healthcare Conference on August 12, 2015
3- V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and infectious diseases, announced today that it will present at the 2015 Wedbush PacGrow Healthcare Conference in New York, NY. Merdad Parsey, Chief Executive Officer, is scheduled to present on Wednesday, August 12th at 1:55p.m. ET.
8/3/15 - Abbott Laboratories' Trademark Application for "XCEED" Filed
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for " XCEED" by Cheryl A. Withycombe, representing Abbott Laboratories. The owner/registrar information for this application is: Cheryl A. Withycombe, Abbott Labor
8/3/15 - Acceleron Pharma Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jul. 16, 2015)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acceleron Pharma Inc. was posted on July 16, 2015. The SEC file number is 0001179110-15-011227.. A U.S. Securities and Exchange Commission filing is
8/3/15 - Access to Kitabis Pak Expands for Patients with Cystic Fibrosis
By a News Reporter-Staff News Editor at Clinical Trials Week There is positive news for patients with cystic fibrosis using nebulized antibiotic therapy as access to Kitabis Pak has expanded in many US states. Kitabis Pak is now on the Preferred Drug List for many state programs, increasing access to the only FDA approved co-packaging of tobramyc
8/3/15 - Achillion Announces Janssen Initiated Phase I Study to Evaluate Effect of Simeprevir and Odalasvir on AL-335 Pharmacokinetics
Achillion Pharmaceuticals, Inc. announced today that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies has initiated a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir on the pharmacokinetics of AL-335 in healthy volunteers. This phase I study is an open-label, two-group study of simeprevir and...
8/3/15 - Achillion Announces That Janssen Has Initiated a Phase I Study to Evaluate the Effect of Simeprevir and Odalasvir (ACH-3102) on AL-335 Pharmacokinetics
Achillion Pharmaceuticals, Inc. announced today that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies has initiated a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir on the pharmacokinetics of AL-335 in healthy volunteers.. As previously announced on May 19, 2015, Achillion has granted Janssen
8/3/15 - Achillion Announces That Janssen Has Initiated a Phase I Study to Evaluate the Effect of Simeprevir and Odalasvir (ACH-3102) on AL-335... [Daily Tribune (Bahrain)]
-Achillion Pharmaceuticals, Inc. announced today that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies has initiated a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir on the pharmacokinetics of AL-335 in healthy volunteers. As previously announced on May 19, 2015, Achillion has granted Janssen a
8/3/15 - Acorda Awarded Grant to Study ARCUS Technology in Respiratory Distress Syndrome
By a News Reporter-Staff News Editor at Clinical Trials Week Acorda Therapeutics, Inc. announced that the Bill& Melinda Gates Foundation has awarded the Company a $1.4 million grant to support the development of a formulation and delivery system for a dry powder version of lung surfactant, a drug used to treat neonatal respiratory distress syndro
8/3/15 - ADMA Biologics Announces Submission of RI-002 Biologics License Application (BLA) to FDA [National News Agency (Lebanon)]
These results, included in the submission, more than meet the requirement specified by the FDA guidance of? We believe that RI-002, if approved by the FDA, has great potential to provide meaningful clinical improvement for patients living with PI, as well as offers clinicians a much needed option for their immune compromised patients. The FDA revie
8/3/15 - Agios Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jul. 17, 2015)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Agios Pharmaceuticals Inc. was posted on July 17, 2015. The SEC file number is 0001209191-15-061528.. A U.S. Securities and Exchange Commission filin
8/3/15 - AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 12, 2015
Applied Genetic Technologies Corporation, a clinical stage biotechnology company developing adeno-associated virus- based gene therapies for the treatment of rare eye diseases, today announced that Sue Washer, President and CEO will present at the Wedbush PacGrow Healthcare Conference on August 12, 2015 at 9:45am ET in New York. Ms. Washer will d
8/3/15 - AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 12, 2015 [Daily Tribune (Bahrain)]
-Applied Genetic Technologies Corporation, a clinical stage biotechnology company developing adeno-associated virus- based gene therapies for the treatment of rare eye diseases, today announced that Sue Washer, President and CEO will present at the Wedbush PacGrow Healthcare Conference on August 12, 2015 at 9:45am ET in New York. Ms. Washer will di
8/3/15 - Allergan Plc Files SEC Form 8-K, Current Report (Jul. 17, 2015)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Allergan Plc was posted on July 17, 2015. The SEC file number is 0001193125-15-256007.. A U.S. Securities and Exchange Commission filing is a formal
8/3/15 - Allergan Plc Files SEC Form S-4, Registration of Securities, Business Combinations (Jul. 17, 2015)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Allergan Plc was posted on July 17, 2015. The SEC file number is 0001193125-15-256030.. A U.S. Securities and Exchange Commission filing is a formal
8/3/15 - Allergan's Trademark Application for "RESTASIS MULTIFREE" Filed
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "RESTASIS MULTIFREE" by Susan J. Hinchey, representing Allergan. The owner/registrar information for this application is: Susan J. Hinchey, Allergan, 2525 Dupo
8/3/15 - Amgen Submits Supplemental New Drug Application For Kyprolis Carfilzomib In Relapsed Multiple Myeloma
By a News Reporter-Staff News Editor at Pharma Business Week Amgen announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for Kyprolis for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one p
8/3/15 - An Application for the Trademark "ABBOTTLINK" Has Been Filed by Abbott Laboratories
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "ABBOTTLINK" by Michele H. Bowman, representing Abbott Laboratories. This application was made available to the public on July 17, 2015. The owner/registrar in
8/3/15 - An Application for the Trademark "ELEVA" Has Been Filed by Abbott Laboratories
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "ELEVA" by Elisa M. Valenzona, representing Abbott Laboratories. The owner/registrar information for this application is: Elisa M. Valenzona, Abbott Laboratori
8/3/15 - An Application for the Trademark "RESTASIS PURETEC" Has Been Filed by Allergan
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "RESTASIS PURETEC" by Susan J. Hinchey, representing Allergan. The owner/registrar information for this application is: Susan J. Hinchey, Allergan, 2525 Dupont
8/3/15 - An Application for the Trademark "SIMILAC ELEVA" Has Been Filed by Abbott Laboratories
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "SIMILAC ELEVA" by Elisa M. Valenzona, representing Abbott Laboratories. The owner/registrar information for this application is: Elisa M. Valenzona, Abbott La
8/3/15 - Antares Pharma to Host Second Quarter 2015 Operating and Financial Results Conference Call
Antares Pharma, Inc. today announced it will release its second quarter 2015 financial results before the market opens on Monday, August 10, 2015, and host a webcast and conference call shortly thereafter at 8:30 a.m. ET to discuss the results. Callers should reference the Antares Pharma conference call or conference identification code 2596882. Ca
8/3/15 - Antares Pharma, Inc. Files SEC Form 3, Initial Statement of Beneficial Ownership of Securities (Jul. 16, 2015)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Antares Pharma, Inc. was posted on July 16, 2015. The SEC file number is 0001209191-15-061206.. A U.S. Securities and Exchange Commission filing is a
8/3/15 - Antares Pharma, Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jul. 16, 2015)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Antares Pharma, Inc. was posted on July 16, 2015. The SEC file number is 0001209191-15-061213.. A U.S. Securities and Exchange Commission filing is a
8/3/15 - Antares Pharma, Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities [Amend] (Jul. 22, 2015)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Antares Pharma, Inc. was posted on July 22, 2015. The SEC file number is 0001209191-15-062077.. A U.S. Securities and Exchange Commission filing is a
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415